{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:58:01Z","timestamp":1793383081141,"version":"4.5.0"},"reference-count":41,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T00:00:00Z","timestamp":1711411200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"FPI-UAM-2021 predoctoral fellowship","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"FPI-UAM-2021 predoctoral fellowship","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"FPI-UAM-2021 predoctoral fellowship","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"FPI-UAM-2021 predoctoral fellowship","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]},{"name":"Acci\u00f3n Estrat\u00e9gica en Salud 2017\u20132020","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"Acci\u00f3n Estrat\u00e9gica en Salud 2017\u20132020","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"Acci\u00f3n Estrat\u00e9gica en Salud 2017\u20132020","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"Acci\u00f3n Estrat\u00e9gica en Salud 2017\u20132020","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]},{"name":"\u201cContrato Margarita Salas de la convocatoria para la Recualificaci\u00f3n del Sistema Universitario Espa\u00f1ol\u201d (UAM)","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"\u201cContrato Margarita Salas de la convocatoria para la Recualificaci\u00f3n del Sistema Universitario Espa\u00f1ol\u201d (UAM)","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"\u201cContrato Margarita Salas de la convocatoria para la Recualificaci\u00f3n del Sistema Universitario Espa\u00f1ol\u201d (UAM)","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"\u201cContrato Margarita Salas de la convocatoria para la Recualificaci\u00f3n del Sistema Universitario Espa\u00f1ol\u201d (UAM)","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]},{"name":"Instituto de Salud Carlos III (ISCIII, Spain)","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"Instituto de Salud Carlos III (ISCIII, Spain)","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"Instituto de Salud Carlos III (ISCIII, Spain)","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"Instituto de Salud Carlos III (ISCIII, Spain)","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda (AEG)","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda (AEG)","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda (AEG)","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"Asociaci\u00f3n Espa\u00f1ola de Gastroenterolog\u00eda (AEG)","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]},{"name":"Spanish Ministry of Health\u2014Social Services and Equality","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"Spanish Ministry of Health\u2014Social Services and Equality","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"Spanish Ministry of Health\u2014Social Services and Equality","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"Spanish Ministry of Health\u2014Social Services and Equality","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]},{"name":"European Social Fund","award":["ICI20\/00131"],"award-info":[{"award-number":["ICI20\/00131"]}]},{"name":"European Social Fund","award":["PI17\/0008"],"award-info":[{"award-number":["PI17\/0008"]}]},{"name":"European Social Fund","award":["ISCIII-Proteored 2019"],"award-info":[{"award-number":["ISCIII-Proteored 2019"]}]},{"name":"European Social Fund","award":["JR19\/00005"],"award-info":[{"award-number":["JR19\/00005"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Proton pump inhibitors (PPIs) are the first-line drug for eosinophilic esophagitis (EoE), although it is estimated that there is a lack of histological remission in 50% of patients. This research aimed to identify pharmacogenetic biomarkers predictive of PPI effectiveness and to study their association with disease features. Peak eosinophil count (PEC) and the endoscopic reference score (EREFS) were determined before and after an eight-week PPI course in 28 EoE patients. The impact of the signal transducer and activator of transcription 6 (STAT6), CYP2C19, CYP3A4, CYP3A5, and ABCB1 genetic variations on baseline PEC and EREFS, their reduction and histological response, and on EoE symptoms and comorbidities was analyzed. PEC reduction was higher in omeprazole-treated patients (92.5%) compared to other PPIs (57.9%, p = 0.003). STAT6 rs12368672 (g.18453G&gt;C) G\/G genotype showed higher baseline PEC values compared to G\/C and C\/C genotypes (83.2 vs. 52.9, p = 0.027). EREFS reduction in STAT6 rs12368672 G\/G and G\/C genotypes was higher than in the C\/C genotype (36.7% vs. \u221275.0% p = 0.011). However, significance was lost after Bonferroni correction. Heartburn incidence was higher in STAT6 rs167769 (g.27148G&gt;A) G\/G patients compared to G\/A (54.55% vs. 11.77%, p = 0.030). STAT6 rs12368672G&gt;C and rs167769G&gt;A variants might have a relevant impact on EoE status and PPI response. Further research is warranted to clarify the clinical relevance of these variants.<\/jats:p>","DOI":"10.3390\/ijms25073685","type":"journal-article","created":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T11:34:58Z","timestamp":1711452898000},"page":"3685","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of STAT6 Variants on the Response to Proton Pump Inhibitors and Comorbidities in Patients with Eosinophilic Esophagitis"],"prefix":"10.3390","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1951-2626","authenticated-orcid":false,"given":"Paula","family":"Soria-Chacartegui","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Navares-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Molina-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Gastroenterology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-7667","authenticated-orcid":false,"given":"Emilio J.","family":"Laserna-Mendieta","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Gastroenterology Department, Hospital General de Tomelloso, 13700 Ciudad Real, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Castilla-La Mancha (IDISCAM), 45071 Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2132-9350","authenticated-orcid":false,"given":"Laura","family":"Arias-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Gastroenterology Department, Hospital General de Tomelloso, 13700 Ciudad Real, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Castilla-La Mancha (IDISCAM), 45071 Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Majano","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Gastroenterology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Cellular Biology Department, Faculty of Biology, Universidad Complutense de Madrid, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6131-8341","authenticated-orcid":false,"given":"Sergio","family":"Casabona","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Gastroenterology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1183-1072","authenticated-orcid":false,"given":"Alfredo J.","family":"Lucendo","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"},{"name":"Gastroenterology Department, Hospital General de Tomelloso, 13700 Ciudad Real, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria de Castilla-La Mancha (IDISCAM), 45071 Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6519-8885","authenticated-orcid":false,"given":"Francisco","family":"Abad-Santos","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5492-2535","authenticated-orcid":false,"given":"Cecilio","family":"Santander","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"},{"name":"Gastroenterology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6150-4320","authenticated-orcid":false,"given":"Pablo","family":"Zubiaur","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Aut\u00f3noma de Madrid (UAM), 28006 Madrid, Spain"},{"name":"Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS-IP), 28006 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.dld.2021.05.025","article-title":"Proton Pump Inhibitor Therapy Reverses Endoscopic Features of Fibrosis in Eosinophilic Esophagitis","volume":"53","author":"Navarro","year":"2021","journal-title":"Dig. Liver Dis."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhernov, Y.V., Vysochanskaya, S.O., Sukhov, V.A., Zaostrovtseva, O.K., Gorshenin, D.S., Sidorova, E.A., and Mitrokhin, O.V. (2021). Molecular Mechanisms of Eosinophilic Esophagitis. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222413183"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.jaci.2023.07.021","article-title":"IL-13-Induced STAT3-Dependent Signaling Networks Reguate Esophageal Epithelial Proliferation in Eosinophilic Esophagitis","volume":"152","author":"Marella","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2019.11.011","article-title":"Diagnosis and Treatment of Eosinophilic Esophagitis","volume":"145","author":"Gonsalves","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1053\/j.gastro.2019.09.052","article-title":"Approaches and Challenges to Management of Pediatric and Adult Patients With Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1097\/NOR.0000000000000595","article-title":"Corticosteroids","volume":"38","author":"Kapugi","year":"2019","journal-title":"Orthop. Nurs."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1016\/j.cgh.2020.01.024","article-title":"Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice","volume":"18","author":"Casabona","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1007\/s11894-008-0098-4","article-title":"Pharmacology of Proton Pump Inhibitors","volume":"10","author":"Shin","year":"2008","journal-title":"Curr. Gastroenterol. Rep."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1002\/cpt.2015","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing","volume":"109","author":"Lima","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.cgh.2020.08.020","article-title":"STAT6 Variants Associate With Relapse of Eosinophilic Esophagitis in Patients Receiving Long-Term Proton Pump Inhibitor Therapy","volume":"19","author":"Mougey","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/MPG.0000000000002480","article-title":"CYP2C19 and STAT6 Variants Influence the Outcome of Proton Pump Inhibitor Therapy in Pediatric Eosinophilic Esophagitis","volume":"69","author":"Mougey","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zubiaur, P., Mej\u00eda-Abril, G., Navares-G\u00f3mez, M., Villapalos-Garc\u00eda, G., Soria-Chacartegui, P., Saiz-Rodr\u00edguez, M., Ochoa, D., and Abad-Santos, F. (2021). PriME-PGx: La Princesa University Hospital Multidisciplinary Initiative for the Implementation of Pharmacogenetics. J. Clin. Med., 10.","DOI":"10.3390\/jcm10173772"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2147\/JAA.S274524","article-title":"Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions","volume":"15","author":"Franciosi","year":"2022","journal-title":"J. Asthma Allergy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1177\/2050640616689525","article-title":"Guidelines on Eosinophilic Esophagitis: Evidence-Based Statements and Recommendations for Diagnosis and Management in Children and Adults","volume":"5","author":"Lucendo","year":"2017","journal-title":"United Eur. Gastroenterol. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/cea.12960","article-title":"Gender-Specific Differences in the Molecular Signatures of Adult Eosinophilic Oesophagitis","volume":"47","author":"Gonsalves","year":"2017","journal-title":"Clin. Exp. Allergy"},{"key":"ref_16","first-page":"A06220393","article-title":"No Gender Differences in Patients with Eosinophilic Oesophagitis","volume":"70","author":"Kozon","year":"2023","journal-title":"Dan. Med. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/apt.15957","article-title":"Efficacy of Proton Pump Inhibitor Therapy for Eosinophilic Oesophagitis in 630 Patients: Results from the EoE Connect Registry","volume":"52","author":"Casabona","year":"2020","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_18","unstructured":"(2024, February 01). AEMPS Nomencl\u00e1tor 2023. Available online: https:\/\/www.sanidad.gob.es\/profesionales\/nomenclator.do."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1053\/j.gastro.2017.06.067","article-title":"Epidemiology and Natural History of Eosinophilic Esophagitis","volume":"154","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"ref_20","unstructured":"National Institute of Health (2024, February 01). Single Nucleotide Polymorphism DataBase (dbSNP), Available online: https:\/\/ngdc.cncb.ac.cn\/databasecommons\/database\/id\/1622."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/all.12431","article-title":"Fine-Mapping of IgE-Associated Loci 1q23, 5q31, and 12q13 Using 1000 Genomes Project Data","volume":"69","author":"Sharma","year":"2014","journal-title":"Allergy"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1016\/j.jaci.2012.10.002","article-title":"A Meta-Analysis of Genome-Wide Association Studies for Serum Total IgE in Diverse Study Populations","volume":"131","author":"Levin","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Weidinger, S., Gieger, C., Rodriguez, E., Baurecht, H., Mempel, M., Klopp, N., Gohlke, H., Wagenpfeil, S., Ollert, M., and Ring, J. (2008). Genome-Wide Scan on Total Serum IgE Levels Identifies FCER1A as Novel Susceptibility Locus. PLoS Genet., 4.","DOI":"10.1371\/journal.pgen.1000166"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Tai, C.-C., Medwid, S., Mclntosh, K., Chande, N., Kim, R.B., and Gregor, J. (2024). Impact of CYP2C19 Metabolizer Status on Esophageal Mucosal Inflammation, Acid Exposure, and Motility among Patients on Chronic Proton-Pump Inhibitor Therapy with Refractory Symptoms of Gastroesophageal Reflux Disease. J. Can. Assoc. Gastroenterol., gwae005.","DOI":"10.1093\/jcag\/gwae005"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein","volume":"364","author":"Rekersbrink","year":"2001","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/bcp.13526","article-title":"Developmental Pharmacogenetics of CYP2C19 in Neonates and Young Infants: Omeprazole as a Probe Drug","volume":"84","author":"Zhao","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00228-005-0901-1","article-title":"Effect of CYP2C19 and MDR1 Polymorphisms on Cure Rate in Patients with Acid-Related Disorders with Helicobacter Pylori Infection","volume":"61","author":"Pawlik","year":"2005","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1185\/03007995.2014.980500","article-title":"Long-Term Effect on Symptoms and Quality of Life of Maintenance Therapy with Esomeprazole 20 Mg Daily: A Post Hoc Analysis of the LOTUS Trial","volume":"31","author":"Lundell","year":"2015","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/apt.13194","article-title":"Long-term Safety of Proton Pump Inhibitor Therapy Assessed under Controlled, Randomised Clinical Trial Conditions: Data from the SOPRAN and LOTUS Studies","volume":"41","author":"Attwood","year":"2015","journal-title":"Aliment Pharmacol. Ther."},{"key":"ref_30","first-page":"e5563","article-title":"The Safety of Long-Term Daily Usage of a Proton Pump Inhibitor: A Literature Review","volume":"11","author":"Abbas","year":"2019","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.4068\/cmj.2023.59.2.115","article-title":"Adverse Effects Associated with Long-Term Use of Proton Pump Inhibitors","volume":"59","author":"Maideen","year":"2023","journal-title":"Chonnam Med. J."},{"key":"ref_32","unstructured":"PharmVar (2024, January 10). Pharmacogene Variation Consortium. Available online: https:\/\/www.pharmvar.org\/."},{"key":"ref_33","unstructured":"PharmGKB (2024, January 10). Tips for Publishing Pharmacogenomic Studies. Available online: https:\/\/www.pharmgkb.org\/page\/curationTips."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.cgh.2017.12.019","article-title":"Eosinophilic Esophagitis Reference Score Accurately Identifies Disease Activity and Treatment Effects in Children","volume":"16","author":"Wechsler","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1111\/all.15779","article-title":"Proteomic Analysis of the Esophageal Epithelium Reveals Key Features of Eosinophilic Esophagitis Pathophysiology","volume":"78","author":"Casabona","year":"2023","journal-title":"Allergy"},{"key":"ref_37","unstructured":"(2024, January 10). World Medical Association World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects. Available online: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Vijayananthan, A., and Nawawi, O. (2008). The Importance of Good Clinical Practice Guidelines and Its Role in Clinical Trials. Biomed. Imaging Interv. J., 4.","DOI":"10.2349\/biij.4.1.e5"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_40","unstructured":"PharmGKB (2024, January 15). PGx Gene-Specific Information Tables. Available online: https:\/\/www.pharmgkb.org\/page\/pgxGeneRef."},{"key":"ref_41","unstructured":"(2024, January 15). DPWG Annotation of DPWG Guideline for Quetiapine and CYP3A4. Available online: https:\/\/www.pharmgkb.org\/guidelineAnnotation\/PA166265421\/clinicalAnnotations."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3685\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:18:45Z","timestamp":1760105925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/7\/3685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,26]]},"references-count":41,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["ijms25073685"],"URL":"https:\/\/doi.org\/10.3390\/ijms25073685","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,26]]}}}